Durbin is reimagining patient access. We are dedicated to improving patient access to unlicensed medicines worldwide. Committed to quality and integrity, Durbin delivers its services with a ‘can-do’ attitude. Durbin pioneered the first global Expanded Access Program (EAP) for a gene therapy and have continued to develop our experience and innovate in the area. We are actively partnered with companies, from small biotechs to large pharma, to develop their strategy for cell and gene therapy EAPs, and to operationalise programs to enable patient access.
Durbin is part of the Uniphar Group. Uniphar is expressly focussed on the specialist treatments and orphan drug markets on a global level. The wide span of capabilities ensures that almost any requirement by a pharma company can be fulfilled.